CASE STUDY

Diffuse alveolar hemorrhage after use of a fluoropolymer-based waterproofing spray

Ryota Kikuchi, Masayuki Itoh, Tomonori Uruma, Takao Tsuji, Hidehiro Watanabe, Hiroyuki Nakamura and Kazutetsu Aoshiba*

Abstract

A 30-year-old man developed chills, cough and dyspnea a few minutes after using a fluoropolymer-based waterproofing spray in a small closed room. He visited our hospital 1 h later. Examination revealed that the patient had incessant cough, tachypnea, fever and decreased peripheral arterial oxygen saturation. Blood tests revealed leukocytosis with elevated serum C-reactive protein levels. Chest radiographs and computed tomography (CT) scan showed bilateral ground glass opacities, mainly in the upper lobes. Bronchoalveolar lavage (BAL) fluid obtained from the right middle lobe showed a bloody appearance. Microscopic examination of a BAL cytospin specimen revealed the presence of numerous red blood cells associated with extreme neutrophilia. Microbiological studies of the BAL fluid were negative. The patient was observed without corticosteroid therapy, and his symptoms and abnormal shadows on the chest radiographs and CT improved. On day 7 after admission, the patient was discharged from the hospital. Accidental inhalation of waterproofing spray may cause diffuse alveolar hemorrhage, a rare manifestation of acute lung injury. Supportive treatment may be effective and sufficient.

Keywords: Alveolar hemorrhage, Waterproofing spray, Fluoropolymer, Respiratory insufficiency, Dyspnea

Case presentation

A 30-year-old Japanese male, a smoker with no significant past medical, allergy or cocaine use history, developed chills, cough and dyspnea a few minutes after using a fluoropolymer-based waterproofing spray on his leather uniforms in a small closed room. He presented to our hospital 1 h later. Examination revealed that the patient had incessant cough, tachypnea (30 breaths per minute), fever (39.4°C) and slightly decreased peripheral arterial oxygen saturation [percutaneous oxygen saturation (SpO₂): 92% on room air]; however, there were no lung crackles or wheeze. Examination of the cardiovascular system revealed no abnormalities. There was no weight loss, arthralgia or skin rash. As shown in Table 1, the blood tests revealed leukocytosis [20,300 cells/μL (normal, 4,000–8,000 cells/μL) with 91.5% neutrophils, 0% eosinophils and 6.5% lymphocytes], elevated serum C-reactive protein levels [3.14 mg/dL (normal, <0.3 mg/dL)] and elevated serum LDH levels [341 U/l (normal, 106–220 U/l)]. Autoimmune screening, including for anti-neutrophil cytoplasm antibody (ANCA) and anti-glomerular basement membrane (anti-GBM) antibody, revealed no autoantibodies. The serum brain natriuretic peptide (BNP) level and coagulation profile were normal. Urinalysis showed no proteinuria or hematuria. Chest radiographs and computed tomography (CT) scan showed bilateral ground glass opacities, mainly in the upper lobes (Figure 1). Fiberoptic bronchoscopy was performed 13 h after the onset of the symptoms. Bronchoalveolar lavage (BAL) fluid obtained from the right middle lobe showed a bloody appearance (Figure 2, left). While the upper lobes appeared to be predominantly involved, the middle lobe was selected for obtaining the BAL sample, because this lobe is the smallest and yields the largest return (Baughman 2007). Microscopic examination of a BAL cytospin specimen revealed the presence of numerous red blood cells with extreme neutrophilia (differential neutrophil count 79.8%, normal range <3%) (Figure 2, right). The siderophage count was less than 2%. Microbiological studies of the BAL fluid were negative.

*Correspondence: kaoshiba@tokyo-med.ac.jp
Department of Respiratory Medicine, Tokyo Medical University Ibaraki Medical Center, 3-20-1 Chuou, Ami, Inashiki, Ibaraki 300-0395, Japan

© 2015 Kikuchi et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
The patient was observed without corticosteroid therapy, and his symptoms improved significantly by the day after admission. By day 7 after admission, the abnormal shadows on the chest radiographs and CT scan had almost completely disappeared and the patient was discharged from the hospital. At 6 months after discharge, his health status was normal. Consent to publish this case report was obtained from the patient.

### Discussion

Accidental inhalation of waterproofing spray has been reported to cause lung injury (Vernez et al. 2006). Diffuse alveolar hemorrhage (DAH) is a rare, but serious manifestation of acute lung injury (Fukui et al. 2011). DAH in this patient was unlikely to be due to immune causes such as microscopic polyangiitis, systemic lupus erythematosus or Goodpasture’s syndrome, because of the absence of weight loss, arthralgia, proteinuria, hematuria, anti-nuclear antibody, anti–anti-GBM antibody or ANCA (Picard et al. 2010). Furthermore, neither congestive heart failure nor coagulopathy could be considered as the likely cause of the DAH, because the serum BNP level and coagulation profile were normal.

The toxicity of waterproofing sprays is thought to be due to their content of water-repellents, such as fluoropolymers and silicon polymers, or of the solvent in which they are delivered (Picard et al. 2010). Among different repellent agents, fluoropolymers have been the most studied with regard to their toxicity following inhalation (Hays and Spiller 2014). An animal study in mice demonstrated that inhalation of fluoropolymers resulted in pulmonary collapse and pneumonia, probably by counteracting the surfactant action in the alveoli of the lung, whereas mice exposed to non-fluoropolymer-containing products showed less severe injury (Yamashita and Tanka 1995). These findings suggest that the fluoropolymer

### Table 1 Laboratory data on admission

| Hematology        |  |
|-------------------|---|
| White blood cells | 20,300/μl (H) |
| Neutrophils       | 91.5% (H) |
| Eosinophils       | 0.0% |
| Basophils         | 0.0% |
| Lymphocytes       | 6.5% |
| Monocytes         | 2.0% |
| Hemoglobin        | 16.5 g/dl |
| Platelets         | 273,000/μl |

| Biochemistry      |  |
|-------------------|---|
| Total protein     | 7.0 g/dl |
| Albumin           | 4.6 g/dl |
| Blood urea nitrogen | 11.5 mg/dl |
| Creatinine        | 0.97 mg/dl |
| Lactate dehydrogenase | 341 U/l (H) |
| Aspartate aminotransferase | 26 U/l |
| Alanine aminotransferase | 12 U/l |

| Coagulation       |  |
|-------------------|---|
| PT-INR            | 1.06 |
| APTT              | 29.5 s |
| APTT (control)    | 34.0 s |

| Serology          |  |
|-------------------|---|
| C-reactive protein| 3.14 mg/dl (H) |
| KL-6              | 339 U/ml |
| Surfactant protein-D | 17.2 ng/ml |
| B-D-glucan        | <60 pg/ml |
| Brain natriuretic peptide | 10.2 pg/ml |
| Anti-GBM antibody  | <10 U/ml |
| Antinuclear antibody | <40 |
| Anti-ds-DNA antibody | <1.2 IU/ml |
| Anti-SS-A antibody | <10 U/ml |
| Anti-SS-B antibody | <10 U/ml |
| Anti-Scl-70 antibody | <10 U/ml |
| Anti-Jo-1 antibody | – |
| MPO-ANCA          | <1.0 U/ml |
| PR3-ANCA          | <1.0 U/ml |

| Urinalysis        |  |
|-------------------|---|
| Protein           | – |
| Sugar             | – |
| Occult blood      | – |

| Bronchoalveolar lavage (rt B4a) |  |
|-------------------------------|---|
| Recovery rate                 | 53.3% (80/150 ml) |
| Cell count                    | 1.2 × 10⁷/μl |
| Macrophages                   | 20.0% |
| Lymphocytes                   | 0.8% |
| Eosinophils                   | 0.4% |
| Neutrophils                   | 78.8% (H) |
| Siderophages                  | 1.9% |

### Table 1 continued

| Culture                  |  |
|--------------------------|---|
| Bacteria                 | – |
| Mycobacterium tuberculosis | – |

| Cytology               | Class II |
|------------------------|----------|
| PT-INR                 | prothrombin time-international normalized ratio, APTT activated partial thromboplastin time, KL-6 sialylated carbohydrate antigen, Kl-6, anti-GBM antibody, anti-anti-glomerular basement membrane antibody, anti-ds-DNA antibody, anti-double stranded DNA, anti-SS-A antibody, anti-SS-B antibody, anti-Sjögren’s-syndrome-related antigen A antibody, anti-Ss-B antibody, anti-Scl-70 antibody, anti-anti-glomerular basement membrane antibody, anti-SS-A antibody, anti-ds-DNA antibody, anti-SS-B antibody, anti-Scl-70 antibody, PR3-ANCA myeloperoxidase-antineutrophil cytoplasmic antibody, PR3-ANCA proteinase 3-antineutrophil cytoplasmic antibody, H indicates high, – indicates negative. |

The patient was observed without corticosteroid therapy, and his symptoms improved significantly by the day after admission. By day 7 after admission, the abnormal shadows on the chest radiographs and CT scan had almost completely disappeared and the patient was discharged from the hospital. At 6 months after discharge, his health status was normal. Consent to publish this case report was obtained from the patient.
water repellents in waterproofing sprays are responsible for causing the acute respiratory illness following inhalation. The primary structural changes after inhalation of waterproofing sprays in animals include alveolar type I cell necrosis and alveolar type II cell necrosis, with resultant impairment of surfactant secretion, direct counteraction of surfactant action, alveolar atelectasis and hemorrhage (Hays and Spiller 2014). A recent study reported developing an isolated perfused rat lung model to examine the potential of surface tension-active substances in waterproofing sprays to cause pulmonary collapse (Fischer et al. 2012). Other mechanisms of the toxicity of waterproofing sprays include an indirect and complex mechanism requiring metabolic activation with or without interaction with other factors, such as solvents (e.g., n-heptane, hexane and petroleum distillates) and smoking (Hays and Spiller 2014). The mist particle size and the emission rate have also been shown to influence the toxicity of waterproofing sprays (Hays and Spiller 2014; Yamashita et al. 1997).

The commonest symptoms associated with inhalation of fluoropolymer-based waterproofing sprays include non-productive cough and dyspnea, often accompanied by flu-like symptoms (Vernez et al. 2006; Hays and Spiller 2014). The illness develops rapidly, usually within minutes to hours (Vernez et al. 2006; Hays and Spiller 2014). Similar to the case reported herein, there is one previous report of DAH resulting from inhalation of a waterproofing spray (Fukui et al. 2011). Laboratory studies generally reveal evidence of acute inflammation such as

**Figure 1** A radiograph (left) and high resolution CT scan (right) of the chest showing bilateral ground glass opacities.

**Figure 2** Bloody gross appearance (left) and microscopic findings (right) of bronchoalveolar lavage fluid specimens. Right May-Giemsa-stained cytospin preparation showing numerous red blood cells and neutrophils, consistent with the diagnosis of alveolar hemorrhage. Arrows macrophages. Scale bar 50 μm.
leukocytosis and elevated serum CRP (Hays and Spiller 2014). In one previous case report, marked hypocalcemia was observed in the patient, which was attributed to the binding activity of fluoride to cations, such as calcium (Bracco and Favre 1998). Serious outcomes and death are uncommon (Vernez et al. 2006; Hays and Spiller 2014). Most victims, even those that present DAH, like our patient, improved with supportive care, with or without corticosteroid and inhaled β2 adrenergic agonist therapy (Vernez et al. 2006; Fukui et al. 2011; Hays and Spiller 2014).

Conclusions
Accidental inhalation of waterproofing sprays may cause diffuse alveolar hemorrhage, a rare manifestation of acute lung injury. Supportive treatment may be effective and sufficient.

Authors' contributions
RK and KA wrote the manuscript. MI, TU, HW and HN revised it critically. All authors read and approved the final manuscript.

Acknowledgements
The authors do not have any financial support to declare.

Compliance with ethical guidelines
The authors declare that they have no competing interests.

Received: 4 January 2015   Accepted: 2 June 2015
Published online: 17 June 2015

References
Baughman RP (2007) Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure. Semin Respir Crit Care Med 28(5):475–485
Bracco D, Favre JB (1998) Pulmonary injury after ski wax inhalation exposure. Ann Emerg Med 32(5):616–619
Fischer M, Koch W, Windt H, Dasenbrock C (2012) A pilot study on the treatment of acute inhalation toxicity studies: the isolated perfusion rat lung as a screening tool for surface-active substances. Altern Lab Anim 40(4):199–209
Fukui Y, Tanino Y, Doshita K, Nakano H, Okamoto Y (2011) Diffuse alveolar hemorrhage arising after use of a waterproofing spray. Nihon Kokyuki Gakkai Zasshi 49(5):360–364 (Article in Japanese)
Hays HL, Spiller H (2014) Fluoropolymer-associated illness. Clin Toxicol 52(8):848–855
Picard C, Cadranel J, Porcher R, Prigent H, Levy P, Fartoukh M et al (2010) Alveolar haemorrhage in the immunocompetent host: a scale for early diagnosis of an immune cause. Respiration 80(4):315–320
Vernez D, Bruzzi R, Kupferschmidt H, De-Batz Droz P, Lazor R (2006) Acute respiratory syndrome after inhalation of waterproofing sprays: a posteriori exposure-response assessment in 102 cases. J Occup Environ Hyg 3(5):250–261
Yamashita M, Tanaka J (1995) Pulmonary collapse and pneumonia due to inhalation of a waterproofing aerosol in female CD-1 mice. J Toxicol Clin Toxicol 33(4):631–637
Yamashita M, Yamashita M, Tanaka J, Hirai H, Suzuki M, Kaigaya H (1997) Toxicity of waterproofing spray is influenced by the mist particle size. Vet Hum Toxicol 39(6):332–334